Aspen Aerogels Inc (ASPN) — SEC Filings
Aspen Aerogels Inc (ASPN) — 42 SEC filings. Latest: 10-K/A (Mar 23, 2026). Includes 22 8-K, 6 10-Q, 3 SC 13G/A.
View Aspen Aerogels Inc on SEC EDGAR
Overview
Aspen Aerogels Inc (ASPN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K/A filed on Mar 23, 2026: ASPEN AEROGELS INC (ASPN) filed a 10-K/A on March 23, 2026, primarily to correct a scrivener's error in its audit report regarding inventory balances. The original filing incorrectly stated inventories at $47.6 million as of December 31, 2025, which was the December 31, 2024 balance. The corrected f
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 39 neutral. The dominant filing sentiment for Aspen Aerogels Inc is neutral.
Filing Type Overview
Aspen Aerogels Inc (ASPN) has filed 1 10-K/A, 22 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 3 SC 13G/A, 2 SC 13D/A, 2 DEFA14A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of ASPN's 33 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $229.764M |
| Net Income | ($316.639M) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $150.722M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Robert J. Gagne
- Dr. Michael J. Molnar
- Gregg Landes
- Ricardo Rodriguez
- Dr. Robert J. Smith
- Ms. Jennifer L. Johnson
- Mr. Don Young
- Mr. Mark T. Weintraub
- Steven R. Mitchell
- Raffaele G. Fazio
- Robert M Gervis
Industry Context
Aspen Aerogels operates in the advanced materials sector, specifically focusing on aerogel technology for thermal insulation. Key markets include energy industrial and electric vehicles (EVs). The company faces competition from other insulation providers and potentially emerging material technologies. The demand for high-performance insulation in EVs and energy efficiency solutions presents growth opportunities, but also requires significant R&D and manufacturing investment.
Top Tags
sec-filing (6) · executive-compensation (5) · financial-reporting (5) · governance (4) · 8-k (3) · 10-Q (3) · proxy-statement (3) · corporate-governance (3) · amendment (3) · financial-condition (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Inventories | $38.2M | Corrected balance as of December 31, 2025, down from $47.6M in 2024. |
| Revenue | $271.1M | For the year ended December 31, 2025, a 40.1% decrease from $452.7M in 2024. |
| Net Loss | ($389.6M) | For the year ended December 31, 2025, a significant reversal from $13.4M net income in 2024. |
| Impairment of property, plant and equipment | $286.6M | Primarily related to the Statesboro Plant in 2025. |
| Total Assets | $406.7M | As of December 31, 2025, a 54.5% decrease from $895.1M in 2024. |
| Basic Net Loss Per Share | ($4.73) | For the year ended December 31, 2025, compared to $0.17 net income per share in 2024. |
| Shares Outstanding | 82.7M | As of December 31, 2025. |
| Cash and cash equivalents | $150.722M | As of September 30, 2025, down from $220.882M at December 31, 2024. |
| Net cash provided by operating activities | $16.737M | For the nine months ended September 30, 2025, compared to $9.865M in 2024. |
| Capital expenditures | $34.985M | For the nine months ended September 30, 2025, down from $71.511M in 2024. |
| Common stock outstanding | 82,647,081 | As of November 4, 2025. |
| Term Loan Facility | $125.0M | Aggregate principal amount of the MidCap Loan Facility drawn in August 2024. |
| Available under Revolving Facility | $26.8M | As of September 30, 2025. |
| Q2 2025 Revenue | $75.2M | Increased 36.5% from $55.1M in Q2 2024, showing strong growth. |
| Q2 2025 Net Loss | -$10.5M | Improved from -$18.2M in Q2 2024, indicating progress towards profitability. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aspen Aerogels Inc (ASPN)?
Aspen Aerogels Inc has 42 recent SEC filings from Jan 2024 to Mar 2026, including 22 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ASPN filings?
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 39 neutral. The dominant sentiment is neutral.
Where can I find Aspen Aerogels Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aspen Aerogels Inc (ASPN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aspen Aerogels Inc?
Key financial highlights from Aspen Aerogels Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ASPN?
The investment thesis for ASPN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aspen Aerogels Inc?
Key executives identified across Aspen Aerogels Inc's filings include Dr. Robert J. Gagne, Dr. Michael J. Molnar, Gregg Landes, Ricardo Rodriguez, Dr. Robert J. Smith and 6 others.
What are the main risk factors for Aspen Aerogels Inc stock?
Of ASPN's 33 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Aspen Aerogels Inc?
Forward guidance and predictions for Aspen Aerogels Inc are extracted from SEC filings as they are enriched.